INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID-) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.

Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study / G. Marasco, C. Cremon, M.R. Barbaro, D. Salvi, G. Cacciari, A. Kagramanova, D. Bordin, V. Drug, E. Miftode, P. Fusaroli, S.Y. Mohamed, C. Ricci, M. Bellini, M.M. Rahman, L. Melcarne, J. Santos, B. Lobo, S. Bor, S. Yapali, D. Akyol, F.P. Sapmaz, Y.Y. Urun, T. Eskazan, A. Celebi, H. Kacmaz, B. Ebik, H.C. Binicier, M.S. Bugdayci, M.B. Yağcı, H. Pullukcu, B.Y. Kaya, A. Tureyen, İ. Hatemi, E.S. Koc, G. Sirin, A.R. Calıskan, G. Bengi, E.E. Alıs, S. Lukic, M. Trajkovska, K. Hod, D. Dumitrascu, A. Pietrangelo, E. Corradini, M. Simren, J. Sjolund, N. Tornkvist, U.C. Ghoshal, O. Kolokolnikova, A. Colecchia, J. Serra, G. Maconi, R. De Giorgio, S. Danese, P. Portincasa, M. Di Stefano, M. Maggio, E. Philippou, Y.Y. Lee, A. Venturi, C. Borghi, M. Zoli, P. Gionchetti, P. Viale, V. Stanghellini, G. Barbara. - In: THE AMERICAN JOURNAL OF GASTROENTEROLOGY. - ISSN 0002-9270. - 117:1(2022 Jan), pp. 147-157. [10.14309/ajg.0000000000001541]

Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study

C. Ricci;G. Maconi;
2022

Abstract

INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID-) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.
COVID-19; Egypt; Europe; Female; Gastroenteritis; Humans; Interviews as Topic; Male; Middle Aged; Prevalence; Prospective Studies; Russia; Surveys and Questionnaires; SARS-CoV-2
Settore MED/12 - Gastroenterologia
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
File Dimensione Formato  
Marasco et al. Am J Gastroenterol 2022.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 779.53 kB
Formato Adobe PDF
779.53 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/931934
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
social impact